Abstract Library

#2980 Metabolic Dysregulation and Circadian Clock in Cellular Models of Neuroendocrine Tumors

Introduction: The circadian clock genes encode transcription factors whose interaction with nuclear receptors allows the regulation of cellular metabolism.The invalidation of the genes of the clock core is associated with the development of many endocrine diseases including neuroendocrine cancer. Recently, the family of transcriptional coactivators PGC-1a has been identified as a key element in the integration of cellular metabolic state with the circadian clock. PRC, as a member of the PGC-1 family, was able to interact with several transcription factors, including the CLOCK factor. The specific induction of this PRC factor by the cell cycle, to modulate the energy function, the MAPkinase pathway and the expression of microRNAs, makes it a key factor in the metabolic adaptation of cancer cells.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Savagner F

Authors: Savagner F, Le Pennec S,

Keywords: Metabolism, Circadian clock, cell models,

#2975 Next Generation Sequencing of Pancreatic Neuroendocrine Tumors in Russian Cohort

Introduction: The appearance of next generation sequencing (NGS), - a powerful high-performance method, allowed accumulation of a large amount of information concerning genetic and epigenetic patterns, however, the problem of matching clinical, histological picture with genetic structure in pNETs remains open.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Trifanov V

Authors: Trifanov V, Kit O, Timoshkina N, Gvaldin D, Karnauhov N,

Keywords: Next generation sequencing, pancreatic neuroendocrine tumors,

#2944 Soluble ST2 (sST2) Levels in the Management of Carcinoid Heart Disease in Patients with Neuroendocrine Cancer

Introduction: The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Salvatici M, Zorzino L, Fabiani I, Cardinale D, Fazio N,

Keywords: sST2, Biomarkers, Carcinoid Heart Disease,

#2817 METNET: A Phase II Trial of Metformin in Patients with Well Differentiated Neuroendocrine Tumors

Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Glasberg J

Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,

Keywords: neuroendocrine tumors, metformin, clinical trial,

#2816 Germline Variants in Cancer Predisposing Genes in Young Adults with Neuroendocrine Tumors

Introduction: Advances in genomics have enabled the recognition of new cancer predisposing genes (CPG). There are few studies of CPG in neuroendocrine tumors (NET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Riechelmann R

Authors: Riechelmann R, de Paula C, Donadio M, Barros M, Formiga M,

Keywords: hereditary syndrome, neuroendocrine tumors, germline variants,